| Similar Articles |
|---|
 |
The Motley Fool
December 18, 2009
Rich Smith |
This Just In: Upgrades and Downgrades UBS goes drilling in the oil patch. On Thursday, UBS established new buy ratings for a trio of deepwater oil drillers: Transocean, Pride International, and Diamond Offshore.   |
The Motley Fool
November 17, 2008
Rich Smith |
This Just In: Upgrades and Downgrades Bank of America analysts aren't terribly impressed with most drug companies. But they did give thumbs up to two. |
The Motley Fool
December 12, 2008
Rich Smith |
This Just In: Upgrades and Downgrades Soleil Securities hands out "buy" ratings to Sepracor, Cephalon, Endo Pharm, and Pfizer. |
The Motley Fool
March 23, 2009
Rich Smith |
This Just In: Upgrades and Downgrades Swiss investment banker UBS wades into the troubled U.S. auto sector with a fistful of ratings, including "buys" for Ford and Johnson Controls. |
The Motley Fool
November 27, 2009
Rich Smith |
This Just In: Upgrades and Downgrades UBS says, "No thanks" to NRG Energy. |
The Motley Fool
June 30, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Major Wall Street investment house Soleil Securities downgraded Eli Lilly shares to "sell." |
The Motley Fool
September 16, 2009
Rich Smith |
This Just In: Upgrades and Downgrades Everybody loves eBay. |
The Motley Fool
April 27, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Johnson Controls announced a "beat and raise" quarter, outstripping analyst profit estimates by $0.04 per share and promising to repeat the feat later this year. The news convinced Wall Street's R.W. Baird to up its rating on the stock to "outperform." |
The Motley Fool
July 7, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Swiss megabanker UBS came out with an upgrade to "buy" for Spirit AeroSystems. Investors, responding to the call, have sent the shares soaring. |
The Motley Fool
December 14, 2009
Rich Smith |
This Just In: Upgrades and Downgrades Piper Jaffray plays a wrong note on Teva. |
The Motley Fool
August 10, 2009
Rich Smith |
This Just In: Upgrades and Downgrades Goldman hearts Merck. Should you? |
The Motley Fool
July 2, 2010
Rich Smith |
This Just In: Upgrades and Downgrades UBS likes the stock of UPS and FedEx. It's half-right. |
The Motley Fool
September 8, 2010
Rich Smith |
This Just In: Upgrades and Downgrades UBS trashes Hewlett-Packard. |
The Motley Fool
May 20, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Standpoint Research has just taken the "unprecedented during our seven years in business" move of recommending five stocks at once, all on a single day: Accenture... Dell... Hewlett-Packard... Teva... Xerox... |
The Motley Fool
October 28, 2009
Rich Smith |
This Just In: Upgrades and Downgrades Citi changes its opinion on Target stores. |
The Motley Fool
November 25, 2009
Rich Smith |
This Just In: Upgrades and Downgrades UBS downgrades Union Pacific, citing how railroad stocks have outperformed the S&P 500 since Warren Buffett's purchase of Burlington Northern. |
The Motley Fool
July 31, 2009
Rich Smith |
This Just In: Upgrades and Downgrades UBS boots up for video games, is optimistic on some e-commerce businesses, neutral on others. |
The Motley Fool
July 21, 2009
Rich Smith |
This Just In: Upgrades and Downgrades Credit Suisse is sweet on Cisco. |
The Motley Fool
February 22, 2005
Charly Travers |
Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list. |
The Motley Fool
August 4, 2010
Rich Smith |
This Just In: Upgrades and Downgrades UBS takes on Applied Materials. |
The Motley Fool
May 17, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Even as Netflix launches a double-edged attack on the Blockbuster business model, its shares were foiled by a triple-downgrade last week. |
The Motley Fool
October 9, 2009
Rich Smith |
This Just In: Upgrades and Downgrades Banker R.W. Baird has come out with a blessing -- and a buy rating -- on Adobe stock. |
The Motley Fool
March 17, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Optimism wafted through the markets this week as UBS upgraded shares of Starbucks to "buy". |
The Motley Fool
August 12, 2010
Jordan DiPietro |
7 Burned-Out Drug Stocks These 5-star drug stocks have been beaten down to attractive levels. |
The Motley Fool
August 12, 2011
David Williamson |
What Happened to U.S. Pharma? How did the domestic pharmaceutical industry fare in the most recent quarter? |
The Motley Fool
July 22, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Baird turns bullish on Human Genome Sciences. |
The Motley Fool
May 7, 2007
Rich Smith |
This Just In: Upgrades and Downgrades In a nutshell, what we have here is an airline with close to the worst operating profitability of any of its major rivals. And yet, it's being valued at a price-to-sales ratio that suggests it's top of the heap -- when it just isn't so. |
The Motley Fool
August 22, 2008
Rich Smith |
This Just In: Upgrades and Downgrades UBS and JPMorgan talk (auto) shop. Let's take a look at their calls on the U.S. auto parts retail industry. |
The Motley Fool
December 21, 2006
Ryan Fuhrmann |
Dueling Fools: Merck Bear Investors, because of its recent run-up, the risk/reward tradeoff is not very compelling. There are safer, more lucrative ways to invest in the space. |
The Motley Fool
September 28, 2009
Rich Smith |
This Just In: Upgrades and Downgrades UBS upgrades these airline stocks: US Airways... Continental... AMR Corp... UAL Corp... Alaska Air... |
The Motley Fool
June 30, 2011
Brian Orelli |
Biotech Winners of a Repatriation Holiday Biotechs and dividend players will come out ahead. |
The Motley Fool
November 25, 2011
Dan Caplinger |
Has Merck Become the Perfect Stock? Like most other pharma companies, Merck is dealing with the imminent loss of patent protection on one of its blockbuster drugs. |
The Motley Fool
December 18, 2008
Brian Orelli |
Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009. |
The Motley Fool
February 24, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Horrified at the company's performance in the 2010 fiscal first quarter, each of UBS, Jefferies, Stifel Nicolaus, and RBC Capital Markets pulled their "buy" ratings, and downgraded the stock to various flavors of "hold." |
The Motley Fool
February 24, 2011
Jordan DiPietro |
Should You Retire With Merck? Is Merck a good choice for a retirement portfolio? |
The Motley Fool
March 18, 2009
Brian Orelli |
Merck Pummels Pfizer One of these acquisitions is not like the other. |
The Motley Fool
June 2, 2009
Brian Orelli |
ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies. |
The Motley Fool
October 8, 2004
Whitney Tilson |
Blue-Chip Bargains? Sifting through beaten-down stocks may yield some good investments. But be careful, most of these stocks are that way for a reason. |
The Motley Fool
June 23, 2005
Stephen D. Simpson |
Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist? |
The Motley Fool
December 16, 2008
Brian Orelli |
Pfizer Keeps the Change For the first time in decades, investors won't get a dividend increase. |
The Motley Fool
December 31, 2007
Brian Lawler |
Big Pharma 2008 Forecast Roundup Investors, take a look at what 2008 has in store for big pharma. |
The Motley Fool
July 18, 2008
Brian Orelli |
Foolish Forecast: How Quickly Can Merck Turn It Around? Views you can use to get clues on the news. |
The Motley Fool
October 27, 2009
Brian Orelli |
Pfizer's and Merck's Loss Is These Companies' Gain Are Pfizer and Merck too busy integrating now to take advantage of additional acquisitions? |
The Motley Fool
October 22, 2010
Anand Chokkavelu |
7 Big Pharma Stocks Near 52-Week Lows Trolling the bottom for upside potential. |
The Motley Fool
July 8, 2011
Brian Orelli |
Half a Breakup Is Better Than No Breakup at All Pfizer keeps two divisions and puts two on the chopping block. |
The Motley Fool
August 13, 2010
Ilan Moscovitz |
Merck: Dividend Dynamo or Disaster? Just how safe is this dividend? |
The Motley Fool
March 24, 2009
Robert Steyer |
Drugmakers Diversify -- Again Merck and Pfizer choose businesses they once eschewed. |
The Motley Fool
December 23, 2009
Brian Orelli |
2009 Cheers and Jeers for Pharma Unfortunately, it was more of the latter. |
The Motley Fool
November 7, 2011
Dan Caplinger |
Has Pfizer Become the Perfect Stock? The pharma giant still faces the challenge of patent expirations that could outpace its pipeline development. |
The Motley Fool
June 16, 2010
Rich Smith |
This Just In: Upgrades and Downgrades UBS ups its view on BorgWarner. |
